Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引：0
作者：
Åsa Ericsson
Adam Lundqvist
机构：
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 248
页数：11
相关论文
共 157 条
[61]  
Gudbjornsdottir S(undefined)undefined undefined undefined undefined-undefined
[62]  
Carlsson KS(undefined)undefined undefined undefined undefined-undefined
[63]  
Hayes AJ(undefined)undefined undefined undefined undefined-undefined
[64]  
Leal J(undefined)undefined undefined undefined undefined-undefined
[65]  
Gray AM(undefined)undefined undefined undefined undefined-undefined
[66]  
Holman RR(undefined)undefined undefined undefined undefined-undefined
[67]  
Clarke PM(undefined)undefined undefined undefined undefined-undefined
[68]  
Freemantle N(undefined)undefined undefined undefined undefined-undefined
[69]  
Mamdani M(undefined)undefined undefined undefined undefined-undefined
[70]  
Vilsboll T(undefined)undefined undefined undefined undefined-undefined
234567891011